rajdeep kumar 1 year ago

rajdeep

On April 16, 2025, the Delhi High Court delivered a significant judgment in Mankind Prime Labs Private Limited v. Registrar of Trade Marks (C.A.(COMM.IPD-TM) 7/2024), overturning the Trade Mark Registry’s rejection of the trademark “CROSSRELIEF” and directing its registration in Class 5. This decision reinforces key principles of trademark law, including the anti-dissection rule, the distinctiveness of composite marks, and the treatment of generic terms in trademark disputes. This blog delves into the case details, the court’s reasoning, and the broader implications for businesses and intellectual property practitioners.

Case Background

Mankind Prime Labs Private Limited, a subsidiary of Mankind Pharma Limited (India’s fifth-largest pharmaceutical company), applied for registration of the word mark “CROSSRELIEF” in Class 5 (covering medicinal, pharmaceutical, and veterinary preparations) on January 2, 2021, on a “proposed to be used” basis. The Trade Mark Registry issued an Examination Report on January 13, 2021, objecting under Section 11(1) of the Trade Marks Act, 1999, which prohibits registration of marks identical or similar to earlier trademarks for similar goods/services, citing a likelihood of public confusion. The report referenced prior marks but did not specify them in the provided judgment excerpt.

On October 17, 2023, the Examiner of Trade Marks rejected the application, stating that “CROSSRELIEF” was “significantly identical with and/or deceptively similar” to cited marks, covering similar goods/services, and likely to cause confusion. Aggrieved, Mankind Prime Labs appealed to the Delhi High Court under Section 91 of the Trade Marks Act, challenging the rejection as legally flawed.

Key Arguments

Appellant’s Submissions

Mankind Prime Labs, represented by Mr. Hemant Daswani, argued that “CROSSRELIEF” was a distinctive, coined mark deserving registration. Key points included:

1. Distinctive Portmanteau: “CROSSRELIEF” was a composite mark combining “CROSS” (a term associated with medical aid in the pharmaceutical industry) and “RELIEF.” The combination created a unique, arbitrary term with no direct reference to the character or quality of the goods, as supported by F. Hoffmann-La Roche & Co. Ltd. v. Geoffrey Manners & Co. Pvt. Ltd.
2. 
   
3. Anti-Dissection Principle: Citing Ticona Polymers, Inc. v. Registrar of Trade Marks, the appellant emphasized that trademarks must be assessed as a whole, not dissected into components. “CROSSRELIEF” was a singular, non-dictionary term, distinct from the cited marks when viewed holistically.
4. Generic Nature of “CROSS”: The term “CROSS” was descriptive, generic, and publici juris (of public right) in the pharmaceutical context, over which no monopoly could be claimed. Consumers typically disregard such common elements and focus on distinctive parts, as held in J.R. Kapoor v. Micronix India and Indo-pharma Pharmaceuticals Works Ltd. v. Citadel Fine Pharmaceuticals Ltd.
5. Distinct Commercial Identity: Even if “CROSS” and “RELIEF” were generic individually, their combination formed a distinctive composite mark with its own commercial identity, akin to protected portmanteau marks like “Microsoft” and “Infosys,” as noted in Disposafe Health & Life Limited v. Rajiv Nath.
6. No Likelihood of Confusion: The appellant argued that “CROSSRELIEF” was phonetically, visually, and structurally different from the cited marks, eliminating any risk of public confusion.

Respondent’s Position

The Registrar of Trade Marks, despite being served, did not file a reply or contest the appeal, leading the court to close its right to respond. The court proceeded to hear the appellant’s arguments on merits.

Court’s Analysis and Decision

Justice Saurabh Banerjee allowed the appeal, set aside the Examiner’s order, and directed the registration of “CROSSRELIEF.” The court’s reasoning was grounded in the following key findings:

1. Inherent Distinctiveness: The court held that “CROSSRELIEF” was a coined, arbitrary, and fanciful term, not a colloquial or dictionary word. As a composite mark, it lacked inherent meaning and bore no direct connection to the goods/services, aligning with the Supreme Court’s ruling in F. Hoffmann-La Roche. The combination of “CROSS” and “RELIEF” created a new word that did not immediately evoke the original terms without thought.
2. 
   
3. Anti-Dissection Principle: Citing Ticona Polymers, Inc., the court reiterated that trademarks must be evaluated holistically. Dissecting “CROSSRELIEF” into “CROSS” and “RELIEF” was impermissible, as the mark’s distinctiveness lay in its composite form.
4. Generic Nature of “CROSS”: The court recognized “CROSS” as a generic, descriptive term in the pharmaceutical industry, publici juris, and commonly used as a prefix. Consumers would likely ignore this common element and focus on the distinctive “RELIEF” component, reducing the risk of confusion with other marks, as supported by J.R. Kapoor and Indo-pharma.
5. Distinct Commercial Identity: Despite incorporating the generic term “CROSS,” “CROSSRELIEF” as a whole possessed a unique commercial identity, distinguishing it from other marks in Class 5. The court drew parallels with protected portmanteau marks, emphasizing the mark’s arbitrary nature.
6. No Likelihood of Confusion: The court found “CROSSRELIEF” to be phonetically, visually, and structurally distinct from the cited marks, concluding that its registration would not cause confusion among consumers or trade members.
7. No Exclusive Rights Over Components: The court clarified that registration of “CROSSRELIEF” would not grant Mankind Prime Labs exclusive rights over “CROSS” or “RELIEF” individually, protecting the mark as a composite whole.

Implications of the Judgment

This ruling has significant implications for trademark law and practice in India, particularly in the pharmaceutical sector:

1. Strengthening the Anti-Dissection Rule: The decision reinforces that composite marks must be assessed as a whole, preventing registries from rejecting marks based on individual generic components. This is crucial for coined terms in competitive industries like pharmaceuticals.
2. Treatment of Generic Terms: By recognizing “CROSS” as publici juris, the court clarifies that no entity can claim monopoly over common industry terms. This protects fair competition while allowing distinctive composite marks to be registered.
3. Support for Portmanteau Marks: The judgment validates the registrability of portmanteau marks, encouraging businesses to create unique, arbitrary terms that combine generic elements into distinctive wholes.
4. Clarity on Likelihood of Confusion: The court’s finding that “CROSSRELIEF” was distinct from cited marks underscores the importance of holistic comparison (phonetic, visual, and structural) in assessing confusion risks, providing guidance for trademark examiners and applicants.
5. Streamlining Registry Processes: The Registrar’s failure to respond highlights procedural lapses, indirectly urging the Trade Mark Registry to engage actively in appeals to ensure robust adjudication.

Conclusion

The Delhi High Court’s decision in Mankind Prime Labs Private Limited v. Registrar of Trade Marks is a pivotal win for trademark applicants seeking to protect coined, composite marks in competitive sectors. By overturning the rejection of “CROSSRELIEF,” the court reaffirmed the principles of distinctiveness, anti-dissection, and the fair use of generic terms. This ruling offers a clear precedent for pharmaceutical companies and other businesses to secure registration for innovative marks, provided they demonstrate a unique commercial identity.

For intellectual property practitioners, the judgment provides a robust framework to challenge rejections based on overly broad interpretations of similarity or confusion. For businesses, it underscores the value of crafting distinctive, arbitrary marks to strengthen brand identity and market presence. As India’s trademark ecosystem evolves, such decisions foster innovation, clarity, and fairness in trademark registration.